Shingles Vaccine Linked to Reduced Dementia Risk in Landmark Study
A new, large-scale study reveals a compelling connection between shingles vaccination and a significantly lower risk of developing dementia, offering a potential new avenue for preventative care against the devastating neurological condition. Researchers were especially struck by the consistency of the findings across a massive dataset.
The study, recently published in the journal Nature Medicine, analyzed the electronic medical records of over 100 million people in the United States between 2007 and 2023. After accounting for a wide range of variables – including chronic illnesses, demographic factors, prescriptions, and doctor visits – investigators found that individuals who received a shingles vaccine had a lower risk of being diagnosed with dementia.
“The virus that causes shingles, varicella-zoster, remains dormant in nerve cells after chickenpox infection,” explained a professor of medicine at Stanford University and one of the study’s authors. Though, in certain specific cases, the virus fully reactivates.
The research indicates that multiple shingles outbreaks are associated with an increased dementia risk. Individuals who experienced more than one episode of shingles had a seven to nine percent higher risk of dementia three to nine years after their second outbreak compared to those who had only experienced it once.
Vaccination Offers Protection
Both types of shingles vaccines – those containing a live virus and those without – were shown to reduce both the frequency of shingles reactivation and the associated risk of dementia. The study highlighted the benefits of the newer Shingrix vaccine, which contains inactivated parts of the virus. Individuals receiving two doses of Shingrix demonstrated an 18 percent lower risk of dementia five years post-vaccination compared to those who received a single dose of the older Zostavax vaccine (which was withdrawn from the US market in 2020).
Notably,women over 50 who received Zostavax experienced a 35 percent lower risk of dementia three years after vaccination,while women aged 80 to 89 who received two doses of Shingrix saw a 39 percent reduction in risk over the same period. “The results were really remarkable in their consistency,” said the study’s lead author, a senior director of machine learning and artificial intelligence at GSK.
Unraveling the biological Mechanisms
While the correlation between shingles and dementia is becoming increasingly clear, the underlying biological mechanisms remain under investigation. Researchers are exploring several theories. One possibility is that the varicella-zoster virus, even during periods of dormancy or subclinical reactivation, directly impacts brain regions vulnerable to dementia.
Another theory centers on the body’s immune response to the virus. “So it’s not necessarily that the virus itself is attacking brain cells directly, but that the inflammatory response to the presence of this virus is causing problems,” explained an internist at Massachusetts General Hospital. It’s also possible that medications used to manage shingles symptoms could play a role, though further research is needed to determine this.
Implications for Public Health
The findings reinforce previous research, including a study examining over 280,000 adults in Wales, which found a 20 percent lower risk of dementia among those vaccinated against shingles over a seven-year period. Current recommendations already advise shingles vaccination for older adults (typically over 50) and individuals with compromised immune systems.
However,some physicians now believe the evidence is compelling enough to discuss dementia prevention as an additional benefit of vaccination with their patients. A neurologist at UMass Chan Medical School cautioned that the issue could become politicized, potentially fueling mistrust in medicine and vaccinations. “Unfortunately,” she said, “people who are not personally affected by dementia may see this as an attempt to persuade them to receive an needless vaccination.” Despite this concern, she emphasized that vaccination represents a relatively inexpensive and widespread preventative measure. “You want to be able to play with your grandchildren for five more years and be able to drive well for another five years,” she said. “This is priceless.”
A better understanding of the varicella-zoster virus’s potential contribution to neurodegeneration is a crucial step toward developing more effective treatments for dementia, researchers say. The consistency of these findings offers a hopeful signal in the ongoing fight against this debilitating disease.
